Menu
Back to Journals » Drug Design, Development and Therapy » Volume 4
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
Authors Puetz J
Published 28 June 2010 Volume 2010:4 Pages 127—137
DOI https://doi.org/10.2147/DDDT.S6628
Review by Single anonymous peer review
Peer reviewer comments 3
John Puetz
Saint Louis University, Department of Pediatrics, St Louis, Missouri, USA
Abstract: One of the last remaining clinical hurdles in the treatment of people with hemophilia is the development of inhibitors. Alloantibodies or autoantibodies directed at coagulation factors render the infusion of coagulation factor concentrates ineffective, and alternative means must be used to achieve hemostasis. Recombinant factor VIIa (rFVIIa) was developed to control bleeding episodes in hemophilic patients with inhibitors. Clinical efficacy in achieving hemostasis in inhibitor patients was demonstrated by a compassionate-use protocol, as well as in randomized controlled trials. To date, over 1.5 million doses of rFVIIa have been given to inhibitor patients, with an excellent efficacy and safety record. Because of its short half-life, alternative means of dosing and infusing rFVIIa have been explored and are reviewed here.
Keywords: hemophilia, inhibitor, recombinant, factor VIIa, inhibitors
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.